Evommune - Public Comps and Valuation Multiples

Evommune Overview

About Evommune

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Founded

2020

HQ

Employees

Website

evommune.com

Sectors

Biopharmaceuticals

Financials

LTM Revenue $13.0M

LTM EBITDA -$78.1M

EV

$919M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Evommune Financials

As of January 2026, Evommune reported last 12-month revenue of $13.0M and EBITDA of -$78.1M.

In the same period, Evommune achieved -$64.9M in LTM net income.

See Evommune valuation multiples based on analyst estimates

Evommune P&L

In the most recent fiscal year, Evommune reported revenue of $7.0M and EBITDA of -$68.7M.

Evommune expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Evommune valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$13.0M	XXX	$7.0M	XXX	XXX	XXX
Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	-$78.1M	XXX	-$68.7M	XXX	XXX	XXX
EBITDA Margin	-601%	XXX	-982%	XXX	XXX	XXX
EBIT	-$76.4M	XXX	-$70.0M	XXX	XXX	XXX
EBIT Margin	-587%	XXX	-1000%	XXX	XXX	XXX
Net Profit	-$64.9M	XXX	-$66.8M	XXX	XXX	XXX
Net Margin	-499%	XXX	-954%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Evommune including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $13.0M. EBITDA for the last twelve months was -$78.1M. In the most recent fiscal year, Evommune achieved $7.0M in revenue and -$68.7M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$13.0M	Analyst estimates available to subscribers	$7.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	NaN% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$78.1M	Analyst estimates available to subscribers	-$68.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-600.7% EBITDA margin	Analyst estimates available to subscribers	-981.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$76.4M	Analyst estimates available to subscribers	-$70.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-587.4% EBIT margin	Analyst estimates available to subscribers	-1000.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$64.9M	Analyst estimates available to subscribers	-$66.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-499.4% net profit margin	Analyst estimates available to subscribers	-954.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Evommune

This financial data table provides comprehensive performance metrics for Evommune, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Evommune generated $13.0M in revenue over the last twelve months.
The company achieved -$78.1M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$64.9M.

Fiscal Year Performance

In the most recent fiscal year, Evommune reported $7.0M in total revenue.
Fiscal year EBITDA was -$68.7M.
The company maintained a gross profit margin of NaN% in the most recent fiscal year.
EBITDA margin for the fiscal year was -981.8%.
Net profit margin reached -954.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Evommune. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Evommune Stock Performance

Evommune has current market cap of $995M, and EV of $919M.

Market Cap Evolution

Evommune Stock Data

As of February 24, 2026, Evommune's stock price is $32.

See Evommune trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$919M	$995M	XXX	XXX	XXX	XXX	$-5.92

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Evommune Valuation Multiples

Evommune's trades at 70.7x EV/Revenue multiple, and -11.8x EV/EBITDA.

See valuation multiples for Evommune and 15K+ public comps

Evommune Financial Valuation Multiples

As of February 24, 2026, Evommune has market cap of $995M and EV of $919M.

Equity research analysts estimate Evommune's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Evommune has a P/E ratio of -15.3x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$995M	XXX	$995M	XXX	XXX	XXX
EV (current)	$919M	XXX	$919M	XXX	XXX	XXX
EV/Revenue	70.7x	XXX	70.7x	XXX	XXX	XXX
EV/EBITDA	-11.8x	XXX	-11.8x	XXX	XXX	XXX
EV/EBIT	-12.0x	XXX	-12.0x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-15.3x	XXX	-15.3x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-15.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Evommune Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Evommune Margins & Growth Rates

Evommune's last 12 month revenue growth is -52%

Evommune's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.7M for the same period.

Evommune's rule of 40 is -789% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Evommune's rule of X is -731% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Evommune and other 15K+ public comps

Evommune Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	-52%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	-601%	XXX	-601%	XXX	XXX	XXX
EBITDA Growth	20%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-789%	XXX	-653%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-731%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.7M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	918%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	1100%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial